Is prostaglandin E2 a pathogenic factor in amyotrophic lateral sclerosis?

Annals of Neurology

Volumn 59, Issue 6, 2006, Pages 980-983

  Almer, Gabriele ^a,c   Kikuchi, Hitoshi ^a   Teismann, Peter ^a   Przedborski, Serge ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME INHIBITION; FATALITY; GENE MUTATION; MOUSE; NERVE DEGENERATION; NONHUMAN; PARALYSIS; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE DEGENERATION; SPINAL CORD; SURVIVAL;

EID: 33744829478     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20847     Document Type: Article

References (14)

1. Rowland LP. Hereditary and acquired motor neuron diseases. In: Rowland LP, ed. Merritt's textbook of neurology. 9 ed. Philadelphia: Williams & Wilkins, 1995:742-749.
2. Julien JP. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 2001;104:581-591.
3. Aimer G, Guégan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-185.
4. Maihofner C, Probst-Cousin S, Bergmann M, et al. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003;18: 1527-1534.
5. Yasojima K, Tourtellotte WW, McGeer EG, et al. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001;57:952-956.
6. Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000;48:792-795.
7. Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002; 52:771-778.
8. Kiaei M, Kipiani K, Petri S, et al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2005;93:403-411.
9. Almer G, Teismann P, Stevic Z, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002;58:1277-1279.
10. Kostic V, Jackson-Lewis V, De Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277:559-562.
11. Azari MF, Profyris C, Le Grande MR, et al. Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. Eur J Neurol 2005;12:357-364.
12. Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88:576-582.
13. Bilak M, Wu L, Wang Q, et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 2004;56:240-248.
14. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.